Skip Navigation


European Heart Journal Advance Access originally published online on March 21, 2005
European Heart Journal 2005 26(10):951-952; doi:10.1093/eurheartj/ehi216
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
26/10/951    most recent
ehi216v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in EHJ
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Salehian, O.
Right arrow Articles by Chan, K. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Salehian, O.
Right arrow Articles by Chan, K. L.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The European Society of Cardiology 2005. All rights reserved. For Permissions, please e-mail: journals.permissions@oupjournals.org

Should brain natriuretic peptides be measured in patients with aortic valve disease?

Omid Salehian and Kwan L. Chan*

University of Ottawa Heart Institute, 40 Ruskin Avenue, Ottawa, Ontario, Canada

* Corresponding author. Tel: +1613 761 4189; fax: +1613 761 4170. E-mail address: kchan@ottawaheart.ca

The first 10% of the full text of this article appears below.

This editorial refers to ‘Relation of N-terminal pro B-type natriuretic peptide to progression of aortic valve disease’{dagger} by Weber et al., on page 1023

Close to 3% of the population over the age of 65 suffers from significant aortic valve disease, a figure likely to rise in our aging population. The current guidelines reflect the ample evidence supporting surgical intervention in symptomatic patients.1 However, optimal treatment of asymptomatic patients with severe disease remains undetermined. The risk of surgical intervention outweighs the risk of sudden cardiac death in asymptomatic patients with severe aortic . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in EHJ:

Relation of N-terminal pro B-type natriuretic peptide to progression of aortic valve disease
Michael Weber, Roman Arnold, Matthias Rau, Albrecht Elsaesser, Roland Brandt, Veselin Mitrovic, and Christian Hamm
EHJ 2005 26: 1023-1030. [Abstract] [Full Text]